Akabani G - Search Results

1

Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.

Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS. Aurlien E, et al. Among authors: akabani g. Int J Radiat Biol. 2000 Aug;76(8):1129-41. doi: 10.1080/09553000050111604. Int J Radiat Biol. 2000. PMID: 10947126

2

Microdosimetry of astatine-211 using histological images: application to bone marrow.

Akabani G, Zalutsky MR. Akabani G, et al. Radiat Res. 1997 Dec;148(6):599-607. Radiat Res. 1997. PMID: 9399706

3

The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.

Larsen RH, Akabani G, Welsh P, Zalutsky MR. Larsen RH, et al. Among authors: akabani g. Radiat Res. 1998 Feb;149(2):155-62. Radiat Res. 1998. PMID: 9457895

4

Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.

Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Akabani G, et al. Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1259-75. doi: 10.1016/s0360-3016(02)03794-x. Int J Radiat Oncol Biol Phys. 2002. PMID: 12419456

5

Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.

Akabani G, Kennel SJ, Zalutsky MR. Akabani G, et al. J Nucl Med. 2003 May;44(5):792-805. J Nucl Med. 2003. PMID: 12732682 Free article.

6

211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.

Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR. Larsen RH, et al. Among authors: akabani g. J Nucl Med. 1999 Jul;40(7):1197-203. J Nucl Med. 1999. PMID: 10405142 Free article.

7

Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.

McLendon RE, Archer GE, Larsen RH, Akabani G, Bigner DD, Zalutsky MR. McLendon RE, et al. Among authors: akabani g. Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):491-9. doi: 10.1016/s0360-3016(99)00206-0. Int J Radiat Oncol Biol Phys. 1999. PMID: 10487576

8

In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.

Akabani G, Carlin S, Welsh P, Zalutsky MR. Akabani G, et al. Nucl Med Biol. 2006 Apr;33(3):333-47. doi: 10.1016/j.nucmedbio.2005.12.006. Epub 2006 Mar 9. Nucl Med Biol. 2006. PMID: 16631082

9

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.

Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR. Akabani G, et al. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947-58. doi: 10.1016/s0360-3016(99)00500-3. Int J Radiat Oncol Biol Phys. 2000. PMID: 10705017 Clinical Trial.

10

In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.

Carlin S, Akabani G, Zalutsky MR. Carlin S, et al. Among authors: akabani g. J Nucl Med. 2003 Nov;44(11):1827-38. J Nucl Med. 2003. PMID: 14602867 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page